Nevada CCB Launches Investigations Into Three Nevada Dispensaries, Selling Potentially Unsafe Product

NEVADA: The Nevada Cannabis Compliance Board (CCB) has opened investigations into three dispensaries for selling product that twice failed microbial testing.

On March 5, 2020, the Department of Taxation and CCB issued a directive to all dispensary/retail stores to immediately stop selling the product, Cherry OG F3, which failed laboratory testing for yeast and mold, coliforms, Enterobacteriaceae and Aspergillus.

At that time, the CCB instructed dispensary/retail stores to destroy or return the affected product to the cultivator and communicate that they took such action with the State. Despite the CCB’s directive, it appears three dispensaries retained their inventory of Cherry OG and began selling the product again in May.

Approximately 375 grams of the Cherry OG product were sold between May 19, 2020 and June 29, 2020 at the following Retail Stores/Medical Dispensaries:

1. Waveseer of Las Vegas, LLC (Jenny’s Dispensary), 5530 N Decatur Blvd, Las Vegas, NV 89130 (License # 83760475147127946601);

2. Paradise Wellness Center, LLC (Las Vegas ReLeaf), 2244 Paradise Road, Las Vegas, NV 89104 (License # 54283805068313943868); and

3. Desert Aire Wellness, LLC (Sahara Wellness), 420 E Sahara Ave, Las Vegas, NV 89104 (License # 25729455103203031356)

On May 16, 2020, a hold on the product was temporarily lifted due to a CCB error that occurred during an unrelated investigation. However, the CCB’s health and safety advisory remained in effect; and under the directive, dispensaries should not have had the product in their inventory.

The CCB advises those who have purchased the product to avoid consuming it. Consumers should check any Cherry OG products for the source package # 1A404030000076F000006649. The CCB notified the aforementioned dispensaries and initiated investigations which are ongoing. There are no known reports of illness.

Surna Announces Largest Contract In Its History

Announces $2.8 million Sales Contract in July

COLORADO: Surna announced today that it recently signed a sales contract valued at $2.8 million.

The project in Illinois is for a multi-state operator with whom Surna has worked on previous facilities in other states. The facility is approximately 88,000 square feet, of which approximately 66,000 square feet is dedicated to cultivation, drying and processing areas. Surna is under contract to provide a full suite of climate control products and technologies for the cultivation and processing spaces (the mechanical engineering design was done by Surna through a previous contract), supply of major mechanical equipment, SentryIQ environmental controls, and system start-up. While Surna can and does provide MEP design and equipment for a wide range of climate control approaches, in this case the priorities of reducing electrical infrastructure requirements and reducing roof loading, along with the desire for precise control of the facility’s environment, resulted in the selection of a 4-pipe hydronic system. The design has integrated dehumidification, in which Surna is providing its proprietary line of multi-function fan coils, destratification fans, dehumidifiers and heat recovery chillers.

Tony McDonald, CEO commented: “The team at Surna has worked diligently to secure the largest single contract in the Company’s history. Now our operations and controls departments will be hard at work ensuring the delivery of a precisely controlled environment and on-time delivery of equipment to meet our customer’s requirements.”

Helix Technologies Sells Security Guarding Business

COLORADO: Helix Technologies announced today the divestiture of its security guarding business. The strategic decision to sell the guarding unit solidifies Helix’s transition into a pure play technology company focused on the cannabis industry.

The divestiture of the guarding business is expected to increase gross margins and allow management to focus on growing the Company’s scalable, high margin suite of critical technology infrastructure services. Denver-based, Veteran-owned Invicta Group purchased the business and Security ProAdvisors LLC represented Helix in the sale. Helix will use the net proceeds to pay off existing liabilities and strengthen its working capital position.

“We are incredibly proud of what we have accomplished with Helix Security. In a short time, we went from start-up–without a single client– to the undisputed leader in the Colorado security market, clearing the field of well-established, larger competitors, and leveraged that dominant position to expand into higher-margin critical technology infrastructure, and data. Now we will continue to bring that same discipline to bear – focused solely on our core technology strengths and on creating a more streamlined value proposition for investors” said Zachary L. Venegas, Helix Technologies’ Executive Chairman and CEO. “The additional working capital and narrowed focus provided by the divestiture will allow us to accelerate growth and continue shaping the cannabis technology landscape.”

Paul Ballenger, Invicta Group CEO added “This is a tremendous opportunity for us and our investors. Helix built a dominant business, and I could not be more excited to leverage our expertise to continue the rapid growth. Recent social unrest has underlined the need for this type of service, and I am excited to help our clients continue to grow while feeling safe and confident in their future.”

Aphria Announces Strategic Supply Agreement With Canndoc

Aphria now positioned within two of the largest cannabis markets outside of Canada
Agreement with Israeli leader Canndoc provides access to Israel’s largest drugstore chain
Finished product will be co-branded under Aphria and Canndoc brands

CANADA: Aphria Inc., a leading global cannabis company, today announced it has entered into a Strategic Supply Agreement with Canndoc Ltd., a subsidiary of InterCure Ltd., one of Israel’s largest and most established medical cannabis producers.

Under the terms of the Agreement, Aphria will supply Canndoc with dried bulk flower over a two-year period, with the option to extend for two additional terms of two years each, and an option for an additional year after that if the parties agree to terms.  During the first two-year term and each additional term, if applicable, the Company will provide Canndoc with 3,000 kgs. of bulk dried flower, which will be processed into finished product, co-branded under the Aphria and Canndoc brand names, and sold exclusively within the Israeli market.

“We are excited about our strategic partnership with Canndoc, a well-established Israeli leader, and the opportunity to continue to expand our medical cannabis brand internationally,” said Irwin D. Simon, Chairman and Chief Executive Officer, Aphria Inc. “Today’s announcement is about more than a supply agreement. It’s about the strength and quality of our medical brand, Aphria, being continuously validated by the world’s medical cannabis markets, including countries in which we have no distribution today. The Agreement represents a significant step for Aphria, and we look forward to bringing our high-quality medical cannabis products to patients in Israel.”

“We are proud to partner with Aphria, a global leader who shares with us the same quality values and commitments of meeting patients’ needs and improving their quality of life. This is another vote of confidence in Canndoc’s leadership and the Israeli market,” said Ehud Barak, former Israeli Prime Minister and Chairman of the Canndoc Board of Directors.

The strategic partnership will also include the possibility of Aphria and Canndoc collaborating on research initiatives such as clinical trials focused on the use of medical cannabis with leading hospitals and research institutions in Israel and exploring potential collaboration in the EU market.

Now strategically positioned in two of the largest cannabis markets outside of Canada, Germany, one of the most highly sought-after developed medical cannabis markets in the world, and Israel, one of the largest importers of medical cannabis in the world, the Company will continue to leverage its market leadership as it develops its medical cannabis markets internationally.

Canndoc has been pioneering Pharma-Grade cannabis for more than 13 years and has established itself as a well-respected company in the global cannabis industry. In March 2020, Canndoc entered a strategic partnership with Super-Pharm, Israel’s largest drugstore chain, allowing for Canndoc’s products to be distributed across 95 medical cannabis authorized pharmacies and sold to Israel’s growing medical cannabis patient community.

Are We Sleeping On The Women In Cannabis Media?

Recently, 420MEDIA CEO Kerri Accardi sat down with Tracy Lamourie for MJ News to discuss the exciting launch of her groundbreaking new venture A New Cannabis Channel

Here’s a peek into that conversation:

TRACY LAMOURIE: You have been doing some amazing things in the media and the cannabis space, and now you are combining the two in a way that I don’t think people are seeing just how groundbreaking it is!

KERRI ACCARDI: Maybe that’s because we didn’t Press Release our every move!

TRACY: Right! But now you are finally ready to let some of the secrets out! Can you tell us a little bit about the exciting things you have got going right now?

KERRI: Absolutely! I’m the founder of 420MEDIA, a full-service marketing and content creation agency.  Over the past 6 years we have been documenting the legalization of cannabis in the US. Currently we are in the process of launching a cannabis TV channel across ROKU, Apple TV, Firestick TV, Android TV, two mobile apps and online, with original programming, including a docu-series.

We are bringing education through entertainment with unprecedented opportunities for targeted advertising to cannabis and CBD companies.  We are super excited to take a very fragmented space and streamline the information to the mainstream while showcasing products and services in a way the public has yet to see.

There are so many people that they hear about CBD or they hear about the benefits of cannabis,  but they don’t know where to find a product or even worse they try a product that’s called CBD and it doesn’t work and right away they’re judging CBD as nonsense, but when you read the bottle it’s really hemp seed oil or something that doesn’t have CBD in it at all.

We really want to help guide people seeking knowledge. At the end of the day, we all have an endocannabinoid system with receptors for the plant on a molecular level. I don’t think the majority of people really understand that – and when they do it’s going to be a game changer.

TRACY: Absolutely- you’re talking education, you’re talking entertainment, the business of cannabis, literally anything relating to cannabis you will find on this channel. I know to bring something like this together doesn’t happen alone and you really have been able to gather an incredible team, some big names not just from cannabis but from the advertising world, from the world of marketing, from the world of media – you are bringing them all together, can you tell us about some of the people you have behind you and some of their experiences before joining you on this groundbreaking project in the world of cannabis.

KERRI: We have a phenomenal team that has come together absolutely from the mainstream industry. We have Emmy award winners; we have advertising executives – in fact the person who is creating our logo created one of the most iconic advertising campaigns I think ever in the world!

TRACY: Unbelievable!

KERRI: We will put names and more information and promo out over the next few weeks.

TRACY: I’m excited to see this develop. Can you tell me some more about the content, and I know it is incredible – you have got people at the top of their industries from athletics to the medical fields, not just one doctor but probably ten from across America – can you tell us a little bit about the content and the experience of gathering that over the years? I know it is a literal library, or a museum of cannabis history over the last few years.

KERRI:  Yes -we have a massive library of professionally filmed content – literally over 300 pioneers- on camera plus products, music, panels and speakers, and original programming.

Super bowl champion Marvin Washington hosts one of our series which explores cannabis from an athlete’s perspective. We have him in a CBD lab, pharmacy, events, as well as closed sets interviewing fellow NFL players and nurses – so it really is different insights coming through him.

Then we have another series hosted by a nurse and educator Heather Manus that is more geared to the medicinal side of the plant. What is the endocannabinoid system? Dosing, our receptors, what are the products and the different methods of ingestion and how does it affect us. Why is this plant working for people? We have another series called “Faces Of Cannabis” featuring over 30 pioneers sharing their story and insight into cannabis – from Wanda James who is on Netflix right now, to a child named Landon Riddle who is cancer free for seven years and he is nine years old to Dr Dina, the women the show “Weeds” was based on. We have a lot.

To me, in a time that is so divisive – to have over 300 people on camera to camera of different ages, ethnicities, and financial backgrounds that agree on one thing is pretty powerful.

TRACY: I know you have spoken in the past about the personal part of your mission.

KERRI: It’s super simple. I left New York on December 10th, 2013 I left on a mission to educate the world about cannabis.  My Aunt Kathy died. My best friend, my mentor, my everything. She died, and she didn’t have to. She definitely didn’t have to suffer like I watched.

I knew that no one would listen to me unless I knew what I was talking about, so I started at the bottom, literally – learning how to grow, meeting with patients, doctors, growers, lobbyists and more. This was back in 2013 in CA – it was a much different world.

In January 2014 NY quazi- legalized medical cannabis through executive order and thus 420MEDIA was born.

TRACY: What a journey. Somewhere your aunt is smiling down on you right now saying, ‘WOW! I inspired all this.’  You really are changing the world with this.  That’s not just language, people are going to see that as this develops – it’s going to be epic.

KERRI: What people don’t understand is that cannabis isn’t new, this medicine isn’t new, even the cannabis industry isn’t new – it’s new in the regulated space. California has been legal-ish for over twenty years and has been helping thousands of people.

TRACY : Now let’s talk a little about the business of cannabis, and I know from a business perspective it’s often difficult to get your message out in the space, struggles around advertising, struggles around restrictions and limitations on social media, lots of barriers about getting your message out there that we don’t face in messaging with other consumer products. So what you are doing is absolutely valuable to people in the cannabis marketing space.  Can you tell us a little bit about this really unprecedented advertising opportunity?

KERRI:  Everything was born out of a problem, and the problem is that brands do not have a place to advertise consistently. I learned about this over the past 6 years of owning an agency and having different television deals and advertising opportunities. They can just change their mind and the rules and the pricing and all sorts of craziness. This was created to enhance cannabis brands and products and give them a place to advertise and share their information very similar to television and TV commercials and when we go back into production we will have opportunity for product placement and sponsorships, so it is a space that will literally give brands the opportunity to showcase their product in high level content that has a truly targeted audience – because you aren’t coming to this channel to watch a baseball game.  You are coming to this channel to learn about cannabis

What’s the value of your athlete CBD cream being seen in a series hosted by a Super Bowl champion who also happens to have a case going to the Supreme Court over the legality of cannabis? What does it mean to have your brand showcased amongst medical professionals discussing the benefits of cannabis?

TRACY: So right now, can companies get involved? Right now, is there opportunity?

KERRI: Yes! What we are doing now, given the COVID-19 situation, is selling permanent placement in three of our series where we will build in commercials to showcase those brands and services. If you are in a series with Marv Washington, for example, you are in there forever. So, brands are getting multiple digital assets and a lifetime value. If they don’t have a commercial, we can have it created for a slight up-charge. If they do have a commercial, they can send it to us, and it will literally be edited in as if it was a part of that series. It is only for our inaugural series!

TRACY: So right now, anyone can get in on the ground floor, in there forever, they can basically write their own story right now as far as where they want to be.  As a publicist and a marketing person, I’m definitely excited about this for my own brand and for my clients, it’s great to be able to get in on the very beginning.

OLCC Rules Advisory Committee Meetings Added Substances in Marijuana Rules Package AUDIO

OREGON:  The OLCC has released the audio from the July 29, 2020 Licensee and Industry RAC. The topic of the advisory meeting was draft rules concerning additives and added substances in the states legal marijuana products.

Listen to the audio here:

 

FSD Pharma Announces Decision To Surrender Health Canada Licenses For Subsidiary FV Pharma Inc.

FV Pharma to shut down operations within 30 days

CANADA: FSD Pharma Inc. today announced that it has notified Health Canada of the Company’s decision to forfeit the licenses of its wholly-owned subsidiary, FV Pharma, Inc.  and suspend all activities by FV Pharma within 30 days of the notification date. FSD Pharma has begun the process of liquidating all FV Pharma assets, including the sale of the Company’s cannabis production facility in Cobourg, Ontario.

“It is now clear to us that our shareholder value is best served in closing down our medicinal grade cannabis operation in Cobourg, Ontario and reinforcing steps to advance pharmaceutical R&D efforts on our lead compound FSD201 (ultra-micronized PEA) and continuing to explore the acquisition of other compelling compounds to expand our drug development pipeline,” said Raza Bokhari, MD, Executive Co-Chairman & CEO.

“Our pharmaceutical R&D team led by Dr. Edward Brennan is actively working to submit an Investigational New Drug Application (IND) to the FDA for the use of FSD201 (ultra-micronized PEA) to treat hospitalized COVID-19 patients by down-regulating the over-expressed pro-inflammatory cytokine immune response to SARS-CoV-2 virus infection. We are hopeful to initiate the phase 2 clinical trial before the end of this year and remain cautiously optimistic that our study may improve treatment outcome for COVID-19 patients.”

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

CalCPA Cannabis Industry Symposium Examines Impact Of COVID-19, Regulation & Economic Outlook On CA’s $3 Billion Cannabis Sector

CALIFORNIA: COVID-19 has wreaked havoc on the California economy, and the cannabis sector has not been immune. Supply chains have been disrupted, revenues have taken a hit, and labor has been impacted. California’s cannabis industry is feeling the pain and seeking a path to recovery through economic stimulus, innovation and new business models, and solid advice from key advisors like CPAs who guide them through complex tax, accounting and auditing matters.

On August 7, 2020, CalCPA will again bring together leading experts and thinkers at its annual Cannabis Industry Virtual Symposium, where attendees will learn about the latest tax, legal and accounting updates impacting cannabis industry businesses and the professionals who advise them. Speakers will provide insight into new, recently implemented policies, outcomes from the COVID-19 stimulus legislation, interpretation of tax law, review of banking rules, trends in federal legislative actions, how to handle bankruptcy and receivership, and valuation of cannabis businesses.

Ohio Medical Marijuana Control Program Releases Testing Laboratory Provisional License Application Materials

OHIO:The Ohio Medical Marijuana Control Program (MMCP) is scheduled to accept new testing laboratory license applications beginning the week of August 3, 2020. On its testing laboratories webpage, the MMCP has posted two documents for potential applicants to assist in understanding the key substantive attributes of the application.

Potential applicants may submit questions regarding the application materials using instructions listed on the testing laboratories webpage. All questions must be submitted by July 31, 2020. The MMCP will then provide the frequently asked questions and MMCP answers to potential applicants.

For more information, visit the MMCP’s testing laboratories webpage.

FDA Issues Draft Guidance To Encourage Cannabis-Related Clinical Research

DISTRICT OF COLUMBIA:  The following quote is attributed to FDA Principal Deputy Commissioner Amy Abernethy M.D., Ph.D.:

“A range of stakeholders have expressed interest in development of drugs that contain cannabis and compounds found in cannabis. Recent legislative changes have also opened new opportunities for cannabis clinical research. As that body of research progresses and grows, the FDA is working to support drug development in this area.

“It is critical that the FDA continues to do what we can to support the science needed to develop new drugs from cannabis. The FDA believes the drug approval process represents the best way to ensure that safe and effective new medicines, including any drugs that contain cannabis or cannabis-derived compounds, are available to patients in need of appropriate medical therapy.

“The agency is committed to supporting the development of these new drugs through the investigational new drug, drug review and drug approval processes – and one key element of this support involves development of guidance, like this one.”

  • The U.S. Food and Drug Administration last week issued “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry,” which describes the FDA’s current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis or cannabis-derived compounds.
  • The draft guidance covers sources of cannabis for clinical research, information on quality considerations and recommendations regarding calculating tetrahydrocannabinol (THC) levels.
  • The draft guidance also introduces key FDA regulatory concepts to stakeholders who may be less familiar with the FDA and the FDA’s authorities.